First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and AdrulipaseBOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced

Related Keywords

Boca Raton , Florida , United States , James Sapirstein , David Schemelia , World Health Organization , Company Annual Report On Form , First Wave Biopharma Inc , Nasdaq , Tiberend Strategic Advisors Inc , Drug Administration , First Wave Bio Inc , Exchange Commission , First Wave Biopharma , Wave Biopharma , Proposed Transaction , First Wave , First Wave Bio , Annual Report , Strategic Advisors , Ulcerative Colitis , Iopharmaceutical Company , Inflammatory Bowel Diseases , Exocrine Pancreatic Insufficiency , Niclosamide , Development Pipeline , Iopharma ,